top of page
31975-site-vettiva-hero3.jpg

Safety and care

31975-site-vettiva-imagem8.jpg

Certificates

We know how important these members of our family are. That is why we value the best safety certifications and, of course, a lot of care in all processes. The medicines developed by Vettiva undergo rigorous manufacturing, validation, and efficacy and safety assessment processes, following national and international regulatory standards. The R&D cycle is 100% carried out in full compliance with comprehensive pharmaceutical regulatory guidelines, with full analytical validation of its active ingredients, inputs, and processes, such as:

Good Laboratory Practices (GLP)

Good Clinical Practices (GCP)

Good Manufacturing Practices (GMP)

The highest certification for drug development and manufacturing: CFR 211.

Our experience in Medicinal Cannabis

Cannabinoids have defined pharmacological targets for multiple indications in veterinary and human medicine

FDA approved drug:

  • Epidiolex (Cannabidiol/CBD) indicated for rare forms of Epilepsy (Lennox-Gastaut & Dravet).

EMA & globally:

  • Sativex (Delta 9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD) 1:1) as an adjunctive treatment for neuropathic pain in patients with multiple sclerosis;

  • Epidiolex.

materia1.png

Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb [published correction appears in Trends Pharmacol Sci. 2009 Dec;30(12):609]. Trends Pharmacol Sci. 2009;30(10):515–527. doi:10.1016/j.tips.2009.07.006

Cannabidiol has acute anti-inflammatory properties and significantly improves mobility in large dogs with osteoarthritis in a double-blind, placebo-controlled veterinary study.

materia2.png

Multiple publications suggest efficacy in osteoarthritis

materia3.png

Oral cannabidiol formulation reduces seizure frequency by 33% in dogs with refractory epilepsy

materia4.png

Placebo Group (n=14)

  • Existing antiepileptic treatment

  • 2.5mg/kg CBD-free oil

Treatment Group (n=12)

  • Existing antiepileptic treatment

  • 2.5mg/kg CBD infused oil

Plasma CBD levels correlated with seizure reduction.

No behavioral side effects reported

  • 2 dogs in the treatment group developed ataxia and were disqualified from the study

Figure 1. Reduction in seizure frequency in dogs with intractable idiopathic epilepsy.

McGrath S, Bartner LR, Rao S, Packer RA, Gustafson DL. Randomized blinded controlled clinical trial to assess the effect of oral cannabidiol administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with intractable idiopathic epilepsy. J Am Vet Med Assoc. (2019) 254:1301–8

Several potential veterinary uses published 

Imagem1.png

Dr. Stephanie McGrath with Atticus, a 3-year-old Saint Bernard enrolled in a clinical trial of cannabidiol for the treatment of epilepsy, and Breonna Thomas, clinical trials coordinator at Colorado State University Veterinary Hospital (Photo by John Eisele/Colorado State University Photography)

*Legal Disclaimer: Vettiva does not sell any products. All current activities of the company are exclusively within the scope of research and development of medicines. All information contained in this website is not for commercial purposes and/or product promotion.

bottom of page